[go: up one dir, main page]

MX2019008462A - Metodo para tratar o mejorar trastornos metabolicos mediante el uso de agonistas del receptor glp-1 conjugados con antagonistas del receptor del peptido inhibidor gastrico (gipr). - Google Patents

Metodo para tratar o mejorar trastornos metabolicos mediante el uso de agonistas del receptor glp-1 conjugados con antagonistas del receptor del peptido inhibidor gastrico (gipr).

Info

Publication number
MX2019008462A
MX2019008462A MX2019008462A MX2019008462A MX2019008462A MX 2019008462 A MX2019008462 A MX 2019008462A MX 2019008462 A MX2019008462 A MX 2019008462A MX 2019008462 A MX2019008462 A MX 2019008462A MX 2019008462 A MX2019008462 A MX 2019008462A
Authority
MX
Mexico
Prior art keywords
glp
gipr
receptor
antagonists
treat
Prior art date
Application number
MX2019008462A
Other languages
English (en)
Inventor
P Miranda Leslie
J Herberich Bradley
Cheng Yuan
Sham Kelvin
Ryan Holder Jerry
Xu Jing
Stanislaus Shanaka
Yie Junming
M Veniant-Ellison Murielle
Wu Bin
NETIROJJANAKUL Chawita
R Falsey James
Lu Shu-Chen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61832572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019008462(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2019008462A publication Critical patent/MX2019008462A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6847—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a hormone or a hormone-releasing or -inhibiting factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proveen métodos para tratar enfermedades y trastornos metabólicos usando una composición que comprende una proteína de unión al antígeno específica para el polipéptido GIPR conjugada a un agonista del receptor GLP-1. En varias modalidades la enfermedad o trastorno metabólico es la diabetes tipo 2, obesidad, dislipidemia, niveles elevados de glucosa, niveles elevados de insulina o nefropatía diabética. En determinadas modalidades la composición comprende un anticuerpo o fragmento funcional de este que comprende una cisteína en uno o más sitio(s) de conjugación donde el agonista del receptor GLP-1 se conjuga al anticuerpo o fragmento funcional de este mediante la cadena lateral del residuo de cisteína.
MX2019008462A 2017-01-17 2018-01-16 Metodo para tratar o mejorar trastornos metabolicos mediante el uso de agonistas del receptor glp-1 conjugados con antagonistas del receptor del peptido inhibidor gastrico (gipr). MX2019008462A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762447332P 2017-01-17 2017-01-17
PCT/US2018/013918 WO2018136440A1 (en) 2017-01-17 2018-01-16 Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)

Publications (1)

Publication Number Publication Date
MX2019008462A true MX2019008462A (es) 2019-11-21

Family

ID=61832572

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008462A MX2019008462A (es) 2017-01-17 2018-01-16 Metodo para tratar o mejorar trastornos metabolicos mediante el uso de agonistas del receptor glp-1 conjugados con antagonistas del receptor del peptido inhibidor gastrico (gipr).
MX2024015311A MX2024015311A (es) 2017-01-17 2019-07-15 Composiciones de agonistas del receptor glp-1 conjugados con anticuerpos que se unen especificamente a gipr humano y usos de las mismas

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024015311A MX2024015311A (es) 2017-01-17 2019-07-15 Composiciones de agonistas del receptor glp-1 conjugados con anticuerpos que se unen especificamente a gipr humano y usos de las mismas

Country Status (38)

Country Link
US (3) US10905772B2 (es)
EP (2) EP3570885B1 (es)
JP (3) JP7175899B2 (es)
KR (3) KR102781241B1 (es)
CN (2) CN110662558B (es)
AR (1) AR110751A1 (es)
AU (2) AU2018210858B2 (es)
BR (1) BR112019014588A2 (es)
CA (1) CA3049023A1 (es)
CL (1) CL2019001963A1 (es)
CO (1) CO2019007685A2 (es)
CR (2) CR20230302A (es)
DK (1) DK3570885T3 (es)
EA (1) EA201991721A1 (es)
ES (1) ES3009462T3 (es)
FI (1) FI3570885T3 (es)
HR (1) HRP20241563T1 (es)
HU (1) HUE069334T2 (es)
IL (2) IL313587A (es)
JO (1) JOP20190177A1 (es)
LT (1) LT3570885T (es)
MA (1) MA47314B1 (es)
MD (1) MD3570885T2 (es)
MX (2) MX2019008462A (es)
NZ (1) NZ754937A (es)
PE (2) PE20250777A1 (es)
PH (1) PH12019501656A1 (es)
PL (1) PL3570885T3 (es)
PT (1) PT3570885T (es)
RS (1) RS66291B1 (es)
SA (1) SA519402246B1 (es)
SG (1) SG11201906525SA (es)
SI (1) SI3570885T1 (es)
SM (1) SMT202400502T1 (es)
TW (1) TWI708613B (es)
UY (1) UY37568A (es)
WO (1) WO2018136440A1 (es)
ZA (1) ZA201904287B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA127495C2 (uk) 2015-12-23 2023-09-13 Амджен Інк. Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
MA49460A (fr) 2017-06-20 2020-04-29 Amgen Inc Méthode de traitement ou de réduction de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1
AU2018288852B2 (en) * 2017-06-21 2025-02-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins
MA68842B1 (fr) * 2017-08-04 2025-01-31 Amgen Inc. Procédé de conjugaison de cys-mabs
CA3131912A1 (en) 2019-03-08 2020-09-17 Amgen Inc. Growth differentiation factor 15 combination therapy
CN112521501A (zh) * 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
US12054551B2 (en) 2020-07-02 2024-08-06 Sanofi FGFR1/KLB targeting agonistic antigen-binding proteins and conjugates thereof with GLP-1R agonistic peptides
JP2023542295A (ja) * 2020-09-14 2023-10-06 リジェネロン ファーマシューティカルズ，インク． Ｇｌｐ１ペプチド模倣薬を含む抗体薬物複合体及びその使用
US20240238380A1 (en) 2021-05-21 2024-07-18 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
EP4352104A4 (en) * 2021-06-09 2025-06-04 Swiftnovo Therapeutics Inc. Therapeutics and methods for treating or ameliorating metabolic disorders
CA3243669A1 (en) * 2022-03-11 2023-09-14 Regeneron Pharmaceuticals, Inc. ANTI-GLP1R ANTIBODY-DRUG CONJUGATES INCLUDING GLP1 PEPTIDOMIMETS AND THEIR USES
CN119744271A (zh) * 2022-09-08 2025-04-01 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与fgf21的融合蛋白，以及其药物组合物和应用
KR102679905B1 (ko) * 2022-10-12 2024-07-02 서울대학교병원 Gipr 마커를 이용한 설폰요소제 의존성 예측용 조성물 및 그 예측 방법
CN120019167A (zh) * 2022-10-12 2025-05-16 首尔大学医院 利用gipr标记物的用于预测磺酰脲类依赖性的组合物及其预测方法
TW202432600A (zh) * 2022-11-07 2024-08-16 美商安進公司 用於治療肥胖症之方法
WO2024123812A1 (en) * 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024209050A1 (en) 2023-04-05 2024-10-10 Antag Therapeutics Aps Gip activity modulators and orthostatic intolerance
WO2024259079A2 (en) * 2023-06-14 2024-12-19 Fractyl Health, Inc. Gene therapies for metabolic disorders
WO2025038435A1 (en) 2023-08-11 2025-02-20 Amgen Inc. Methods of solid phase antibody conjugation
TW202528348A (zh) * 2023-10-31 2025-07-16 大陸商山東博安生物技術股份有限公司 Gipr阻斷型抗體及其抗體偶聯物
WO2025104668A1 (en) 2023-11-17 2025-05-22 Pfizer Inc. Anti-gastric inhibitory polypeptide receptor (gipr) antibodies and antibody conjugates for the treatment of metabolic disorders
WO2025199030A1 (en) * 2024-03-18 2025-09-25 Amgen Inc. Glp-1 receptor agonists and their medical use

Family Cites Families (153)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
CA2111348A1 (en) 1991-06-14 1992-12-23 John S. Logan Production of human hemoglobin in transgenic pigs
CA2113113A1 (en) 1991-07-08 1993-01-21 Simon W. Kantor Thermotropic liquid crystal segmented block copolymer
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
WO1995007463A1 (en) 1993-09-10 1995-03-16 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
WO1998005351A1 (en) 1996-08-08 1998-02-12 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
US7091183B1 (en) 1996-12-03 2006-08-15 Boston Medical Center Corporation Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
WO1998024464A1 (en) 1996-12-03 1998-06-11 Trustees Of Boston University Specific antagonists for glucose-dependent insulinotropic polypeptide (gip)
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
DE69831673C5 (de) 1997-01-07 2015-01-22 Amylin Pharmaceuticals, Llc Verwendung von exedinen und deren antagonisten zur verminderung der lebensmittelaufnahme
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
DE69838791T3 (de) 1997-08-08 2011-06-22 Amylin Pharmaceuticals, Inc., Calif. Neue exendinagonist verbindungen
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU757748B2 (en) 1997-11-14 2003-03-06 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
AU756836B2 (en) 1997-11-14 2003-01-23 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
DE69936446T2 (de) 1998-02-13 2008-03-06 Amylin Pharmaceuticals, Inc., San Diego Inotropische und diuretische effekte von exendin und glp-1
US6232107B1 (en) 1998-03-27 2001-05-15 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
DE69926007T2 (de) 1998-10-07 2005-12-29 Medical College Of Georgia Research Institute, Inc. Glukose-abhängiges, insulinotropisches peptid für die verwendung als osteotropes hormon
CA2352573C (en) 1998-12-07 2012-04-10 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R Glp-1 analogues
ATE307603T1 (de) 1998-12-22 2005-11-15 Lilly Co Eli Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
DK1140145T4 (da) 1999-01-14 2019-07-22 Amylin Pharmaceuticals Llc Hidtil ukendte exendinagonistformuleringer og fremgangsmåder til indgivelse deraf
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
PT1143989E (pt) 1999-01-14 2007-03-30 Amylin Pharmaceuticals Inc Exendinas para supressão de glucagon
DE60012721D1 (de) 1999-03-29 2004-09-09 Uutech Ltd Analoge des magensaft inhibierenden peptides und ihre verwendung für die behandlung von diabetes
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
WO2001022922A2 (en) 1999-09-27 2001-04-05 The Regents Of The University Of California Engineering antibodies that bind irreversibly
DK1246638T4 (da) 2000-01-10 2014-09-22 Amylin Pharmaceuticals Llc Anvendelse af extendiner og agonister deraf til behandlingen af hypertriglyceridæmi
AU2001232735A1 (en) 2000-01-27 2001-08-07 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 compounds
WO2001087341A1 (en) 2000-05-16 2001-11-22 Sanwa Kagaku Kenkyusho Co.,Ltd. Agents for preventing or ameliorating insulin resistance and/or obesity
DK1456360T3 (en) 2001-04-19 2015-08-31 Scripps Research Inst Methods and Composition for Preparation of Orthogonal TRNA-Aminoacyl-TRNA Synthetase Pairs
US20050159379A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
JP4566459B2 (ja) 2001-06-07 2010-10-20 株式会社日立製作所 表示装置
WO2003055914A2 (en) 2001-12-21 2003-07-10 7Tm Pharma A/S Modified receptors for the discovery of therapeutic ligands
JP4417113B2 (ja) 2002-02-20 2010-02-17 エミスフェアー・テクノロジーズ・インク Ｇｌｐ−１分子の投与方法
WO2003097031A1 (en) 2002-05-22 2003-11-27 Sanwa Kagaku Kenkyusho Co., Ltd. Obesity preventive or ameliorator containing methylidene hydrazide compound as active ingredient
US20040029805A1 (en) 2002-06-15 2004-02-12 Wolfe M. Michael Prevention and treatment of nonalcoholic fatty liver disease (NAFLD) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (GIP)
JP2006213598A (ja) 2003-03-19 2006-08-17 Sanwa Kagaku Kenkyusho Co Ltd ピラゾロピリミジン化合物及びその用途
US7452966B2 (en) 2003-06-12 2008-11-18 Eli Lilly And Company GLP-1 analog fusion proteins
EP1663295A2 (en) 2003-09-01 2006-06-07 Novo Nordisk A/S Stable formulations of peptides
RU2378285C2 (ru) 2004-02-11 2010-01-10 Амилин Фармасьютикалз, Инк. Гибридные полипептиды с селектируемыми свойствами
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
US7991890B2 (en) 2004-09-30 2011-08-02 Microsoft Corporation Game console communication with a device
CN101119749A (zh) 2004-10-25 2008-02-06 赛托斯生物技术公司 肠抑胃肽(gip)抗原阵列及其用途
SI1831252T1 (sl) 2004-12-22 2009-12-31 Lilly Co Eli Formulacije analogov glp-1 fuzijskih proteinov
US20060275288A1 (en) 2005-01-20 2006-12-07 Grihalde Nelson D GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
JP2008530130A (ja) 2005-02-11 2008-08-07 アミリン・ファーマシューティカルズ，インコーポレイテッド Ｇｉｐ類似体および選択可能な特性を備えるハイブリッドポリペプチド
EP1882044A1 (en) 2005-05-11 2008-01-30 sanofi-aventis Use of a gip promoter polymorphism
JP5235661B2 (ja) 2005-05-25 2013-07-10 ノボ・ノルデイスク・エー／エス 安定化ポリペプチド製剤
WO2007028633A2 (en) * 2005-09-08 2007-03-15 Uutech Limited Treatment of diabetes related obesity
AU2007227202B2 (en) 2006-03-21 2013-08-22 Amylin Pharmaceuticals, Llc Peptide-peptidase inhibitor conjugates and methods of using same
CA2648936C (en) 2006-04-20 2013-07-09 Amgen Inc. Glp-1 compounds
EP2015776A1 (en) 2006-04-20 2009-01-21 Amgen Inc. Glp-1 compound/glucagon antibody compositions
WO2008006113A2 (en) 2006-07-07 2008-01-10 The Texas A & M University System Novel belactosin derivatives as therapeutic agents/biological probes and their synthesis
US20090209469A1 (en) 2006-08-04 2009-08-20 Dennis Kim Use of Exendins and GLP-1 Receptor Agonists for Altering Lipoprotein Particle Size and Subclass Composition
CA2660835A1 (en) 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. Dpp-iv resistant gip hybrid polypeptides with selectable propperties
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
GEP20135944B (en) 2007-02-15 2013-10-25 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
WO2009042922A2 (en) 2007-09-27 2009-04-02 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of making and using same
US20090144162A1 (en) 2007-11-29 2009-06-04 Neil Milne Transaction Security Method and Apparatus
GB0814068D0 (en) 2008-08-01 2008-09-10 Univ Ulster Active immunisation against GIP
PT2320923E (pt) 2008-08-07 2015-02-24 Ipsen Pharma Sas Análogos truncados de polipéptido insulinotrópico dependente de glucose
WO2010016936A1 (en) 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
JP2011530509A (ja) 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Ｎ末端において修飾されたグルコース依存性インスリン分泌刺激ポリペプチド（ｇｉｐ）のアナログ
CN102170895A (zh) 2008-08-07 2011-08-31 益普生制药股份有限公司 葡萄糖依赖性促胰岛素多肽类似物
US9074014B2 (en) 2008-08-07 2015-07-07 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide
US20120157379A1 (en) 2009-07-31 2012-06-21 Sheau Yu Hsu Gastric Inhibitory Peptide Variants and Their Uses
MX2012008603A (es) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
US9023986B2 (en) 2010-10-25 2015-05-05 Hoffmann-La Roche Inc. Glucose-dependent insulinotropic peptide analogs
CN103458920B (zh) 2010-12-22 2016-07-06 印第安那大学科技研究公司 表现出gip受体活性的胰高血糖素类似物
EP2685257A4 (en) 2011-03-08 2014-10-01 Sanwa Kagaku Kenkyusho Co METHOD OF ANALYSIS
EP2718317B1 (en) 2011-06-10 2018-11-14 Beijing Hanmi Pharmaceutical Co., Ltd. Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof
ES2721882T3 (es) 2011-12-23 2019-08-06 Pfizer Regiones constantes de anticuerpo modificadas por ingeniería genética para conjugación específica de sitio y procedimientos y usos de las mismas
US9745359B2 (en) 2012-05-18 2017-08-29 Adda Biotech Inc. Protein and protein conjugate for diabetes treatment, and applications thereof
WO2014037373A1 (en) 2012-09-07 2014-03-13 Sanofi Fusion proteins for treating a metabolic syndrome
WO2014100913A1 (en) 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
CN104371019B (zh) 2013-08-13 2019-09-10 鸿运华宁（杭州）生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
US20160185837A1 (en) 2013-08-16 2016-06-30 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
CA2932325A1 (en) * 2013-12-04 2015-06-11 Innovative Targeting Solutions Inc. G-protein coupled receptor agonists and methods
WO2015086853A1 (en) 2013-12-13 2015-06-18 Novo Nordisk Health Care Ag Method for thioether conjugation of proteins
ES2846099T3 (es) 2013-12-17 2021-07-28 Mhs Care Innovation Llc Composiciones y métodos para tratar la acumulación de tejidos grasos
SI3129406T1 (sl) 2014-04-11 2019-04-30 Medimmune, Llc Konjugirane spojine, ki vsebujejo cisteinsko konstruirana protitelesa
WO2015185640A1 (en) 2014-06-04 2015-12-10 Novo Nordisk A/S Glp-1/glucagon receptor co-agonists for medical use
SG11201701128YA (en) 2014-09-12 2017-03-30 Genentech Inc Cysteine engineered antibodies and conjugates
US10097078B2 (en) 2014-10-21 2018-10-09 Toshiba International Corporation Multi-mode energy router
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
TWI700291B (zh) 2015-06-22 2020-08-01 美國禮來大藥廠 升糖素及glp-1共激動劑化合物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
UA127495C2 (uk) * 2015-12-23 2023-09-13 Амджен Інк. Виділений антигензв'язуючий білок, який специфічно зв'язується з поліпептидом рецептора шлункового інгібіторного пептиду (gipr) людини, та фармацевтична композиція, яка його містить
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
US20180237095A1 (en) 2017-02-23 2018-08-23 Motive Power Industry Co., Ltd. Two-wheel suspension mechanism
MA49460A (fr) 2017-06-20 2020-04-29 Amgen Inc Méthode de traitement ou de réduction de troubles métaboliques à l'aide de protéines de liaison au récepteur du peptide inhibiteur gastrique (gipr) en association avec des agonistes du glp-1
AU2018288852B2 (en) 2017-06-21 2025-02-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins
MA68842B1 (fr) 2017-08-04 2025-01-31 Amgen Inc. Procédé de conjugaison de cys-mabs

Also Published As

Publication number Publication date
IL267660B2 (en) 2024-11-01
KR20190104158A (ko) 2019-09-06
PL3570885T3 (pl) 2025-03-17
IL267660A (en) 2019-08-29
CL2019001963A1 (es) 2020-04-03
SMT202400502T1 (it) 2025-01-14
EP3570885A1 (en) 2019-11-27
EP4480537A2 (en) 2024-12-25
EA201991721A1 (ru) 2020-04-08
MX2024015311A (es) 2025-01-09
CO2019007685A2 (es) 2019-07-31
AR110751A1 (es) 2019-05-02
JP2025011265A (ja) 2025-01-23
SG11201906525SA (en) 2019-08-27
PH12019501656A1 (en) 2019-10-28
JP2020506900A (ja) 2020-03-05
JOP20190177A1 (ar) 2019-07-16
HUE069334T2 (hu) 2025-02-28
SA519402246B1 (ar) 2023-02-15
US20210154318A1 (en) 2021-05-27
JP2022184880A (ja) 2022-12-13
BR112019014588A2 (pt) 2020-02-18
JP7175899B2 (ja) 2022-11-21
RS66291B1 (sr) 2025-01-31
US10905772B2 (en) 2021-02-02
PE20191467A1 (es) 2019-10-16
US20250121056A1 (en) 2025-04-17
KR20250038835A (ko) 2025-03-19
TWI708613B (zh) 2020-11-01
CN110662558B (zh) 2024-04-09
PE20250777A1 (es) 2025-03-14
HRP20241563T1 (hr) 2025-01-31
CN110662558A (zh) 2020-01-07
MD3570885T2 (ro) 2025-03-31
CR20230302A (es) 2023-08-25
LT3570885T (lt) 2024-12-27
DK3570885T3 (da) 2024-12-16
UY37568A (es) 2018-07-31
US12214051B2 (en) 2025-02-04
ZA201904287B (en) 2025-10-29
AU2018210858A1 (en) 2019-07-18
MA47314A (fr) 2019-11-27
WO2018136440A1 (en) 2018-07-26
FI3570885T3 (fi) 2024-12-18
PT3570885T (pt) 2024-12-16
AU2018210858B2 (en) 2025-02-20
EP4480537A3 (en) 2025-03-12
KR102781241B1 (ko) 2025-03-14
IL313587A (en) 2024-08-01
JP7574253B2 (ja) 2024-10-28
ES3009462T3 (en) 2025-03-27
TW201838648A (zh) 2018-11-01
US20180311372A1 (en) 2018-11-01
MA47314B1 (fr) 2025-01-31
KR102697797B1 (ko) 2024-08-27
CN118079021A (zh) 2024-05-28
CR20190380A (es) 2019-11-07
AU2025201348A1 (en) 2025-03-20
SI3570885T1 (sl) 2025-02-28
NZ754937A (en) 2023-04-28
CA3049023A1 (en) 2018-07-26
EP3570885B1 (en) 2024-09-18
KR20240131457A (ko) 2024-08-30
IL267660B1 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
CO2019007685A2 (es) Método para tratar o mejorar trastornos metabólicos mediante el uso de agonistas del receptor glp-1 conjugados con antagonistas del receptor del péptido inhibidor gástrico (gipr)
CO2018007582A2 (es) Método para tratar o mejorar trastornos metabólicos con proteínas de unión para el receptor peptídico inhibidor gástrico (gipr) en combinación con agonistas de glp-1
PE20200013A1 (es) Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1
PE20190917A1 (es) Compuestos del peptido tirosina ciclico con anticuerpo acoplado como moduladores de receptores de neuropeptido
ECSP19046893A (es) Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip
AR070844A1 (es) Fragmento fab o anticuerpo monoclonal humanizado que comprende el fragmento fab, y su uso para la manufactura de un medicamento antagonista del polipeptido del receptor de glucagon para el tratamiento o prevencion de diabetes de tipo 1 o 2
MX2023012010A (es) Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr).
MX2019007584A (es) Combinaciones de compuesto de fgf21/agonista de glp-1r con una proporcion de actividades optimizada.
AR075998A1 (es) Tratamiento de trastornos resistentes a insulina.composicion farmaceutica. uso. kit
MX2019002437A (es) Metodos para tratar la resistencia severa a la insulina interfiriendo con la señalizacion del receptor de glucagon.
EA201991583A1 (ru) Способ лечения или облегчения метаболических нарушений с использованием белков, связывающих рецептор желудочного ингибиторного пептида (gipr), в комбинации с агонистами glp-1
CL2025002476A1 (es) Anticuerpo contra gipr y su proteína de fusión con glp-1, su composición farmacéutica y aplicación
EA202092810A1 (ru) Способ применения ко-агониста gip/glp1 при диабете